DK2982753T3 - Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes - Google Patents
Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes Download PDFInfo
- Publication number
- DK2982753T3 DK2982753T3 DK15174152.7T DK15174152T DK2982753T3 DK 2982753 T3 DK2982753 T3 DK 2982753T3 DK 15174152 T DK15174152 T DK 15174152T DK 2982753 T3 DK2982753 T3 DK 2982753T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- microspheres
- oligonucleotides
- composition
- antisense
- Prior art date
Links
- 0 C*C(CC1C(C)C(C)C(CC(C2)C(C)C)C2C(*)C(C(*)C(*)C*)[Os])CC1C1C(C(C2)C(C)CC2C(C)C)C=CC1 Chemical compound C*C(CC1C(C)C(C)C(CC(C2)C(C)C)C2C(*)C(C(*)C(*)C*)[Os])CC1C1C(C(C2)C(C)CC2C(C)C)C=CC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Sammensætning omfattende mikrosfærer, hvor mikrosfærerne omfatter et anti-sense-oligonukleotid med i det mindste 90% sekvenshomologi med SEQ ID NO: 4, et antisense-oligonukleotid med i det mindste 90% homologi med SEQ ID NO:6 og et antisense-oligonukleotid med i det mindste 90% homologi med SEQ ID NO:7, til anvendelse som en behandling til inducering af dendritisk celletolerance i et pattedyr, hvor antisense-oligonukleotiderne med i det mindste 90% sekvenshomologi med SEQ ID NO: 4, SEQ ID NO: 6 og SEQ ID NO: 7 er rettede imod og binder til primære transcripter af CD40, CD86 hhv. CD80, hvor anvendelsen omfatter: indgivelse til pattedyret af sammensætningen i en injektion, hvor indgivelsen gentages.
2. Sammensætning til anvendelse ifølge krav 1, hvor injektionen er en subkutan injektion.
3. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor forholdet imellem individuelle antisense-oligonukleotider i mikrosfærerne er 1:1:1 af antisense-oligonucleotider med i det mindste 90% sekvenshomologi med SEQ ID NO:4, SEQ ID NO:6 og SEQ ID NO:7.
4. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor injektionen omfatter imellem omkring 150 milligram (mg) til omkring 500 mg af antisense-oligonukleotider.
5. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor injektionen omfatter en vandig suspension.
6. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor injektionen omfatter imellem omkring 0,01 mg til omkring 1000 mg af mikrosfærer pr. milliliter (ml).
7. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor injektionen omfatter fra 1 ml til mindre end 2 ml.
8. Sammensætning til anvendlese ifølge ethvert af de foregående krav, hvor den gennemsnitlige mikrosfærerstørrelse er mindre end omkring 50 mikrometer.
9. Sammensætning til anvendelse ifølge ethvert af de foregående krav, hvor behandlingen reverserer destruktionen af insulinproducerende betaceller.
10. Anvendelse af mikrosfærer til fremstillingen af et lægemiddel til anvendelse som en behandling til inducering af dendritisk celletolerance i et pattedyr, hvor mikrosfærerne omfatter et antisense-oligonukleotid med i det mindste 90% sekvenshomologi med SEQ ID NO: 4, et antisense-oligonukleotid med i det mindste 90% homologi med SEQ ID NO:6 og et antisense-oligonukleotid med i det mindste 90% homologi med SEQ ID NO:7, hvor antisense-oligonukleotiderne med i det mindste 90% sekvenshomologi med SEQ ID NO: 4, SEQ ID NO: 6 og SEQ ID NO: 7 er rettede imod og binder til primære transkripter af CD40, CD86 hhv. CD80, hvilken anvendelse som en behandling omfatter: indgivelse til pattedyr af sammensætningen i en injektion, hvor indgivelsen gentages.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4603408P | 2008-04-18 | 2008-04-18 | |
US4824608P | 2008-04-28 | 2008-04-28 | |
EP09732817.3A EP2281042B1 (en) | 2008-04-18 | 2009-04-20 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2982753T3 true DK2982753T3 (da) | 2018-09-03 |
Family
ID=40941866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15174152.7T DK2982753T3 (da) | 2008-04-18 | 2009-04-20 | Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes |
DK09732817.3T DK2281042T3 (da) | 2008-04-18 | 2009-04-20 | Mikrokuglebaseret sammensætning til forebyggelse og/eller ophævelse af begyndende autoimmun diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09732817.3T DK2281042T3 (da) | 2008-04-18 | 2009-04-20 | Mikrokuglebaseret sammensætning til forebyggelse og/eller ophævelse af begyndende autoimmun diabetes |
Country Status (12)
Country | Link |
---|---|
US (1) | US8022046B2 (da) |
EP (2) | EP2982753B1 (da) |
JP (4) | JP5685182B2 (da) |
CN (1) | CN102007213B (da) |
AU (1) | AU2009237577B2 (da) |
CA (1) | CA2720675C (da) |
DK (2) | DK2982753T3 (da) |
ES (2) | ES2554168T3 (da) |
HK (1) | HK1221261A1 (da) |
MX (1) | MX2010011508A (da) |
PL (2) | PL2982753T3 (da) |
WO (1) | WO2009129544A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2982753T3 (da) * | 2008-04-18 | 2018-09-03 | Baxter Int | Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes |
EP2640425A2 (en) | 2010-11-18 | 2013-09-25 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
WO2013158868A1 (en) * | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
EP3071688B1 (en) * | 2013-11-18 | 2020-07-08 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies |
CN107849537A (zh) | 2015-06-30 | 2018-03-27 | 西北生物治疗药物公司 | 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞 |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5102872A (en) | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
EP0248531A3 (en) | 1986-05-02 | 1988-09-28 | Southern Research Institute | Encapsulated nucleic acids |
AU612591B2 (en) | 1986-08-11 | 1991-07-18 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
AU598946B2 (en) | 1987-06-24 | 1990-07-05 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
WO1991006556A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp., Bothell, Wash. | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
ES2185615T3 (es) | 1990-05-16 | 2003-05-01 | Southern Res Inst | Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa. |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
ATE154246T1 (de) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
GB9016885D0 (en) | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
HU217036B (hu) | 1990-08-03 | 1999-11-29 | Sanofi | Eljárás génexpresszió gátlására alkalmas vegyületek előállítására |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
HU206372B (en) | 1990-09-03 | 1992-10-28 | Richter Gedeon Vegyeszet | Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
EP0549686A4 (en) | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
DE69232816T2 (de) | 1991-11-26 | 2003-06-18 | Isis Pharmaceuticals Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5525519A (en) | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
JPH05234332A (ja) | 1992-02-18 | 1993-09-10 | Sony Corp | ディスク再生装置 |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
CA2157793C (en) | 1993-03-09 | 1999-07-13 | James E. Woiszwillo | Macromolecular microparticles and methods of production |
AU6449394A (en) | 1993-03-30 | 1994-10-24 | Sterling Winthrop Inc. | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US6218510B1 (en) * | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
US5912340A (en) | 1995-10-04 | 1999-06-15 | Epoch Pharmaceuticals, Inc. | Selective binding complementary oligonucleotides |
US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP2341058A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
JP2002512203A (ja) * | 1998-04-17 | 2002-04-23 | ザ ユニバーシティ オブ バーモント アンド ステイト アグリカルチュラル カレッジ | 疾患における代謝的相互作用に関連する方法および製品 |
SE516700C2 (sv) * | 1999-06-07 | 2002-02-12 | Firefly Ab | Detektorarrangemang |
EP1072679A3 (en) | 1999-07-20 | 2002-07-31 | Agilent Technologies, Inc. (a Delaware corporation) | Method of producing nucleic acid molecules with reduced secondary structure |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
GB0207440D0 (en) * | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
WO2005105840A2 (en) * | 2004-03-26 | 2005-11-10 | Five Prime Therapeutics, Inc. | Cd40 variants and uses thereof |
EP1758558B1 (en) * | 2004-05-12 | 2013-10-16 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
CN1980640A (zh) * | 2004-05-12 | 2007-06-13 | 巴克斯特国际公司 | 核酸微球体,其制备和递送 |
DE602005009954D1 (de) * | 2004-05-12 | 2008-11-06 | Baxter Int | Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe |
EP2295588B1 (en) * | 2004-05-27 | 2018-03-07 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses thefor |
MX2009001226A (es) * | 2006-08-04 | 2009-03-20 | Baxter Int | Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio. |
WO2008109495A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof |
DK2982753T3 (da) * | 2008-04-18 | 2018-09-03 | Baxter Int | Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes |
-
2009
- 2009-04-20 DK DK15174152.7T patent/DK2982753T3/da active
- 2009-04-20 CN CN200980113547.XA patent/CN102007213B/zh active Active
- 2009-04-20 EP EP15174152.7A patent/EP2982753B1/en active Active
- 2009-04-20 US US12/426,904 patent/US8022046B2/en not_active Expired - Fee Related
- 2009-04-20 ES ES09732817.3T patent/ES2554168T3/es active Active
- 2009-04-20 EP EP09732817.3A patent/EP2281042B1/en active Active
- 2009-04-20 WO PCT/US2009/041167 patent/WO2009129544A1/en active Application Filing
- 2009-04-20 MX MX2010011508A patent/MX2010011508A/es active IP Right Grant
- 2009-04-20 ES ES15174152.7T patent/ES2686708T3/es active Active
- 2009-04-20 PL PL15174152T patent/PL2982753T3/pl unknown
- 2009-04-20 AU AU2009237577A patent/AU2009237577B2/en active Active
- 2009-04-20 JP JP2011505257A patent/JP5685182B2/ja not_active Expired - Fee Related
- 2009-04-20 PL PL09732817T patent/PL2281042T3/pl unknown
- 2009-04-20 DK DK09732817.3T patent/DK2281042T3/da active
- 2009-04-20 CA CA2720675A patent/CA2720675C/en active Active
-
2014
- 2014-10-10 JP JP2014208623A patent/JP2015007133A/ja not_active Withdrawn
-
2016
- 2016-08-09 HK HK16109472.0A patent/HK1221261A1/zh not_active IP Right Cessation
- 2016-11-14 JP JP2016221840A patent/JP2017036334A/ja not_active Withdrawn
-
2018
- 2018-09-21 JP JP2018177118A patent/JP2018197274A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
DK2281042T3 (da) | 2015-11-09 |
CN102007213A (zh) | 2011-04-06 |
ES2554168T3 (es) | 2015-12-16 |
EP2281042B1 (en) | 2015-08-26 |
JP2015007133A (ja) | 2015-01-15 |
ES2686708T3 (es) | 2018-10-19 |
JP2018197274A (ja) | 2018-12-13 |
US20090291145A1 (en) | 2009-11-26 |
EP2281042A1 (en) | 2011-02-09 |
CA2720675C (en) | 2019-08-27 |
MX2010011508A (es) | 2011-05-03 |
WO2009129544A1 (en) | 2009-10-22 |
CA2720675A1 (en) | 2009-10-22 |
PL2982753T3 (pl) | 2019-03-29 |
HK1221261A1 (zh) | 2017-05-26 |
JP2011519365A (ja) | 2011-07-07 |
US8022046B2 (en) | 2011-09-20 |
EP2982753B1 (en) | 2018-06-06 |
EP2982753A1 (en) | 2016-02-10 |
JP2017036334A (ja) | 2017-02-16 |
AU2009237577B2 (en) | 2014-06-05 |
PL2281042T3 (pl) | 2016-01-29 |
JP5685182B2 (ja) | 2015-03-18 |
CN102007213B (zh) | 2014-08-06 |
AU2009237577A1 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018197274A (ja) | 初発自己免疫性糖尿病を予防するため、および/または逆転させるためのマイクロスフェアに基づく組成物 | |
US8389493B2 (en) | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes | |
US20210401884A1 (en) | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies | |
AU2013213750B2 (en) | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |